CN1272015C - 阿德福韦酯和聚乙二醇共融物及其制备方法 - Google Patents
阿德福韦酯和聚乙二醇共融物及其制备方法 Download PDFInfo
- Publication number
- CN1272015C CN1272015C CNB2004100010813A CN200410001081A CN1272015C CN 1272015 C CN1272015 C CN 1272015C CN B2004100010813 A CNB2004100010813 A CN B2004100010813A CN 200410001081 A CN200410001081 A CN 200410001081A CN 1272015 C CN1272015 C CN 1272015C
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- adefovir ester
- fused matter
- preparation
- adefovir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002202 Polyethylene glycol Substances 0.000 title claims abstract description 50
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 title abstract description 12
- 229960003205 adefovir dipivoxil Drugs 0.000 title abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 229960001997 adefovir Drugs 0.000 claims description 108
- -1 adefovir ester Chemical class 0.000 claims description 103
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 24
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 24
- 238000005303 weighing Methods 0.000 claims description 23
- 238000002441 X-ray diffraction Methods 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 238000010257 thawing Methods 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 239000013078 crystal Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 claims description 6
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims description 6
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims description 6
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims description 6
- 229940093430 polyethylene glycol 1500 Drugs 0.000 claims description 6
- 229940057847 polyethylene glycol 600 Drugs 0.000 claims description 6
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003973 paint Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 10
- 239000007788 liquid Substances 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 229930182507 Neplanocin Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
时间(月) | 本发明制剂外观 | 主药含量(%) | 有关物质(%) |
0 | 类白色片 | 99.57 | 0.274 |
1 | 类白色片 | 98.94 | 0.341 |
2 | 类白色片 | 98.81 | 0.399 |
3 | 类白色片 | 98.64 | 0.471 |
溶出度(%) | 1 | 2 | 3 | 4 | 5 | 6 | 平均值(%) |
本发明制剂 | 91.17 | 90.54 | 92.82 | 89.19 | 87.06 | 93.51 | 91.41 |
阿德福韦酯原粉制剂 | 68.12 | 65.56 | 66.23 | 65.91 | 68.66 | 67.67 | 67.02 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100010813A CN1272015C (zh) | 2004-02-03 | 2004-02-03 | 阿德福韦酯和聚乙二醇共融物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100010813A CN1272015C (zh) | 2004-02-03 | 2004-02-03 | 阿德福韦酯和聚乙二醇共融物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1557327A CN1557327A (zh) | 2004-12-29 |
CN1272015C true CN1272015C (zh) | 2006-08-30 |
Family
ID=34350562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100010813A Expired - Lifetime CN1272015C (zh) | 2004-02-03 | 2004-02-03 | 阿德福韦酯和聚乙二醇共融物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1272015C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102293776A (zh) * | 2010-06-22 | 2011-12-28 | 天津药物研究院药业有限责任公司 | 阿德福韦酯固体制剂及其制备方法 |
CN105708815A (zh) * | 2016-03-31 | 2016-06-29 | 辰欣药业股份有限公司 | 一种阿德福韦酯片剂及制备方法 |
-
2004
- 2004-02-03 CN CNB2004100010813A patent/CN1272015C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1557327A (zh) | 2004-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1115149C (zh) | 制备氟苯哌苯醚固体分散体的水性方法 | |
CN1102046C (zh) | 口服抗菌组合物 | |
CN1751056A (zh) | 铁有机化合物、其应用及其制备方法 | |
CN1272015C (zh) | 阿德福韦酯和聚乙二醇共融物及其制备方法 | |
CN1307979C (zh) | 紫珠止血滴丸及其制备方法 | |
CN1211391C (zh) | 匹伏阿德福韦的晶体 | |
CN1301098C (zh) | 毛冬青滴丸及其制备方法 | |
CN1319533C (zh) | 盐酸头孢他美酯分散片及其制备方法 | |
CN1626085A (zh) | 左西孟旦冻干制剂及其制备方法 | |
CN1879635A (zh) | 阿德福韦酯的β-环糊精包合物及其制剂 | |
CN1698822A (zh) | 一种治疗肝炎的肝苏滴丸及其制备方法 | |
CN1307981C (zh) | 一种具有止血作用的血宁滴丸及其制备方法 | |
CN1255102C (zh) | 复方尿囊素滴丸 | |
CN1535972A (zh) | 一种新的化合物及其制备方法和以该化合物为活性成分的药物制剂及其作用、用途 | |
CN1682816A (zh) | 一种用于治疗多种癌症的消癌平滴丸及其制备方法 | |
CN1307984C (zh) | 宫颈癌滴丸及其制备方法 | |
CN1307982C (zh) | 一种用于降血脂的脉舒滴丸及其制备方法 | |
CN1307983C (zh) | 一种治疗高脂蛋白血症的脉安滴丸及其制备方法 | |
CN1660373A (zh) | 拳参滴丸及其制备方法 | |
CN1660371A (zh) | 一种治疗细菌感染性疾病的口服滴丸及其制备方法 | |
CN1720964A (zh) | 一种以白屈菜为原料的胃痛平滴丸及其制备方法 | |
CN1634490A (zh) | 一种治疗咽喉疾病的六灵滴丸及其制备方法 | |
CN1709468A (zh) | 以啤酒花浸膏为原料的肺毒清滴丸及其制备方法 | |
CN1660367A (zh) | 金莲花滴丸及其制备方法 | |
CN1682818A (zh) | 灯盏地龙滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right |
Effective date of registration: 20070615 Pledge (preservation): Preservation |
|
PD01 | Discharge of preservation of patent |
Date of cancellation: 20071215 Pledge (preservation): Preservation registration |
|
C56 | Change in the name or address of the patentee |
Owner name: CISEN PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHANDONG LUKANG CISEN PHARMACEUTICAL CO., LTD |
|
CP01 | Change in the name or title of a patent holder |
Address after: 272031 Shandong Province, Jining City Ring Road No. 19 Patentee after: CISEN PHARMACEUTICAL Co.,Ltd. Address before: 272031 Shandong Province, Jining City Ring Road No. 19 Patentee before: SHANDONG LUKANG CISEN PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20180305 Address after: 272300 Shandong city of Jining province Yutai county Zhang Huang Zhen Industrial Park Shandong Chenlong Pharmaceutical Co. Ltd. Patentee after: SHANDONG CHENLONG PHARMACEUTICAL Co.,Ltd. Address before: 272031 Shandong Province, Jining City Ring Road No. 19 Patentee before: CISEN PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060830 |